End-of-day quote
Korea S.E.
03:30:00 26/04/2024 am IST
5-day change
1st Jan Change
3,130
KRW
+0.97%
-0.32%
+12.79%
18/04
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
CI
27/03
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
Sales 2022
38.64B
28.09M
2.34B
Sales 2023
4.88B
3.55M
296M
Capitalization
208B
151M
12.62B
Net income 2022
-23.87B
-17.35M
-1.45B
Net income 2023
-48.92B
-35.57M
-2.96B
EV / Sales 2022
5.93
x
Net cash position
2022
11.83B
8.6M
717M
Net cash position
2023
12.29B
8.93M
744M
EV / Sales 2023
40.2
x P/E ratio 2022
-10.1
x
P/E ratio 2023
-4.2
x
Employees
68
Yield 2022 *
-
Yield 2023
-
Free-Float
77.42%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
18/04
CI
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
27/03
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
18/03
CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2023
15/03
CI
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period
25/01
CI
An unknown buyer cancelled the acquisition of 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc.
14/12
CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
14/11
CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
12/23/12
CI
Crystal Bio Sciences Co., Ltd announced that it has received KRW 10 billion in funding from CrystalGenomics Invites Co., LTD.
12/23/12
CI
CrystalGenomics Invites Co., LTD.(KOSDAQ:A083790) dropped from S&P Global BMI Index
24/23/24
CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
17/23/17
CI
CrystalGenomics, Inc. announced that it has received KRW 62.427998592 billion in funding from New Lake Invites Investment Co., Ltd., Osung Advanced Materials Co., Ltd.
02/23/02
CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/23/15
CI
An unknown buyer agreed to acquire approximately 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc for KRW 28 billion.
30/23/30
CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
22/22/22
CI
More news
1 day +0.97%
1 week -0.32%
Current month -16.53%
1 month -14.48%
3 months +21.55%
6 months +16.57%
Current year +12.79%
More quotes
Managers
Title Age Since
Chief Executive Officer
75
01/00/01
Comptroller/Controller/Auditor
52
-
Members of the board
Title Age Since
Chief Executive Officer
75
01/00/01
Director/Board Member
59
31/17/31
Director/Board Member
64
-
More insiders
Date
Price
Change
Volume
26/24/26
3,130
+0.97%
108,961
25/24/25
3,100
+0.65%
69,045
24/24/24
3,080
-1.60%
73,124
23/24/23
3,130
-2.03%
70,517
22/24/22
3,195
+1.75%
108,095
End-of-day quote
Korea S.E., April 26, 2024
More quotes
CG Invites Co Ltd is a Korea-based company principally engaged in the development and manufacturing of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Research and Development segment is engaged in the research, development and sale of new drugs such as anti-inflammatory painkillers, anticancer drugs, anti-infectives and others. It is also engaged in the real estate rental business. The Pharmaceutical Manufacturing segment is engaged in the manufacture, retail and wholesale of finished drug products. The Other segment is engaged in the manufacture and sale of hot packs and other household items.
More about the company
1st Jan change
Capi.
+12.79% 174M +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1